Top

Published in:

01-06-2009 | Review

Vaccination against atherosclerosis? Induction of atheroprotective immunity

Authors: Göran K. Hansson, Jan Nilsson

Published in: Seminars in Immunopathology | Issue 1/2009

Abstract

Atherosclerosis involves the formation of inflammatory arterial lesions and is one of the most common causes of death globally. It has been evident for more than 20 years that adaptive immunity regulates the magnitude of the atherogenic proinflammatory response. T cells may also influence the stability of the atherosclerotic lesion and thus the propensity for thrombus formation and the clinical outcome of disease. Immunization of hypercholesterolemic animals with low-density lipoprotein preparations reduces atherosclerosis, suggesting that vaccination may represent a useful strategy for disease prevention or modulation. This review summarizes our current understanding of the role immunity in atherosclerosis and outlines strategies for antigen-specific prevention of this disease.

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695. doi:10.1056/NEJMra043430 CrossRefPubMed

Nilsson J, Hansson GK, Shah PK (2005) Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 25:18–28. doi:10.1161/01.ATV.0000174796.81443.3f CrossRefPubMed

Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508–519. doi:10.1038/nri1882 CrossRefPubMed

Yan ZQ, Hansson GK (2007) Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 219:187–203. doi:10.1111/j.1600-065X.2007.00554.x CrossRefPubMed

Peiser L, Mukhopadhyay S, Gordon S (2002) Scavenger receptors in innate immunity. Curr Opin Immunol 14:123–128. doi:10.1016/S0952-7915(01)00307-7 CrossRefPubMed

Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ (2002) Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105:1158–1161PubMed

Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 101:10679–10684. doi:10.1073/pnas.0403249101 CrossRefPubMed

Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT et al (2004) Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10:416–421. doi:10.1038/nm1008 CrossRefPubMed

Mullick AE, Tobias PS, Curtiss LK (2005) Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115:3149–3156. doi:10.1172/JCI25482 CrossRefPubMed

10.

Edfeldt K, Bennet AM, Eriksson P, Frostegård J, Wiman B, Hamsten A, Hansson GK, de Faire U, Yan ZQ (2004) Association of hypo-responsive toll- like receptor 4 variants with risk of myocardial infarction. Eur Heart J 25:1447–1453

11.

Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347:185–192. doi:10.1056/NEJMoa012673 CrossRefPubMed

12.

Bjorkbacka H (2006) Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 17:527–533CrossRefPubMed

13.

Kaartinen M, Penttilä A, Kovanen PT (1994) Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90:1669–1678PubMed

14.

Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St Clair J, Shi GP (2007) Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13:719–724. doi:10.1038/nm1601 CrossRefPubMed

15.

Robertson AK, Hansson GK (2006) T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 26:2421–2432. doi:10.1161/01.ATV.0000245830.29764.84 CrossRefPubMed

16.

Hansson GK, Robertson AKL, Söderberg-Nauclér C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1:297–329. doi:10.1146/annurev.pathol.1.110304.100100 CrossRefPubMed

17.

Bobryshev YV (2000) Dendritic cells and their involvement in atherosclerosis. Curr Opin Lipidol 11:511–517. doi:10.1097/00041433-200010000-00009 CrossRefPubMed

18.

Zhou X, Stemme S, Hansson GK (1996) Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 149:359–366PubMed

19.

Elhage R, Gourdy P, Brouchet L, Jawien J, Fouque MJ, Fievet C, Huc X, Barreira Y, Couloumiers JC, Arnal JF et al (2004) Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am J Pathol 165:2013–2018PubMed

20.

Dansky HM, Charlton SA, Harper MM, Smith JD (1997) T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 94:4642–4646. doi:10.1073/pnas.94.9.4642 CrossRefPubMed

21.

Zhou X, Nicoletti A, Elhage R, Hansson GK (2000) Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102:2919–2922PubMed

22.

Daugherty A, Puré E, Delfel-Butteiger D, Leferovich J, Roselaar SE (1997) The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E−/− mice. J Clin Invest 100:1575–1580. doi:10.1172/JCI119681 CrossRefPubMed

23.

Zhou X, Robertson AK, Hjerpe C, Hansson GK (2006) Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 26:864–870. doi:10.1161/01.ATV.0000206122.61591.ff CrossRefPubMed

24.

Angeli V, Llodra J, Rong JX, Satoh K, Ishii S, Shimizu T, Fisher EA, Randolph GJ (2004) Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21:561–574. doi:10.1016/j.immuni.2004.09.003 CrossRefPubMed

25.

Paulsson G, Zhou X, Törnquist E, Hansson GK (2000) Oligoclonal T cell expansions in atherosclerotic lesions of apoE-deficient mice. Arterioscler Thromb Vasc Biol 20:10–17PubMed

26.

Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK (1995) T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 92:3893–3897. doi:10.1073/pnas.92.9.3893 CrossRefPubMed

27.

Palinski W, Ord V, Plump AS, Breslow JL, Steinberg D, Witztum JL (1994) ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 14:605–616PubMed

28.

Fredrikson GN, Hedblad B, Berglund G, Alm R, Ares M, Cercek B, Chyu KY, Shah PK, Nilsson J (2003) Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 23:872–878. doi:10.1161/01.ATV.0000067935.02679.B0 CrossRefPubMed

29.

Binder CJ, Shaw PX, Chang MK, Boullier A, Hartvigsen K, Horkko S, Miller YI, Woelkers DA, Corr M, Witztum JL (2005) The role of natural antibodies in atherogenesis. J Lipid Res 46:1353–1363. doi:10.1194/jlr.R500005-JLR200 CrossRefPubMed

30.

Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK (2001) Protection against atherosclerosis by LDL immunization is associated with T cell dependent IgG antibodies in apoE-deficient mice. Arterioscler Thromb Vasc Biol 21:108–114. doi:10.1161/hq0901.096582 CrossRefPubMed

31.

Moos MP, John N, Grabner R, Nossmann S, Gunther B, Vollandt R, Funk CD, Kaiser B, Habenicht AJ (2005) The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 25:2386–2391. doi:10.1161/01.ATV.0000187470.31662.fe CrossRefPubMed

32.

Grabner R, Lotzer K, Dopping S, Hildner M, Radke D, Beer M, Spanbroek R, Lippert B, Reardon CA, Getz GS et al (2009) Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE−/− mice. J Exp Med 206:233–248. doi:10.1084/jem.20080752 CrossRefPubMed

33.

Jonasson L, Holm J, Hansson GK (1988) Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc Natl Acad Sci U S A 85:2303–2306. doi:10.1073/pnas.85.7.2303 CrossRefPubMed

34.

Marx SO, Marks AR (2001) Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104:852–855PubMed

35.

Palinski W, Miller E, Witztum JL (1995) Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 92:821–825. doi:10.1073/pnas.92.3.821 CrossRefPubMed

36.

Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, Shah PK, Nilsson J (1996) Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16:1074–1079PubMed

37.

Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL (1996) Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 98:800–814. doi:10.1172/JCI118853 CrossRefPubMed

38.

Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9:736–743. doi:10.1038/nm876 CrossRefPubMed

39.

Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL (2002) Innate and acquired immunity in atherogenesis. Nat Med 8:1218–1226. doi:10.1038/nm1102-1218 CrossRefPubMed

40.

Faria-Neto JR, Chyu KY, Li X, Dimayuga PC, Ferreira C, Yano J, Cercek B, Shah PK (2006) Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189:83–90. doi:10.1016/j.atherosclerosis.2005.11.033 CrossRefPubMed

41.

Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, Kohler HV, Kaveri SV, Nicoletti A (2007) Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 50:540–546. doi:10.1016/j.jacc.2006.11.054 CrossRefPubMed

42.

Sjogren P, Fredrikson GN, Rosell M, de Faire U, Hamsten A, Nilsson J, Hellenius ML, Fisher RM (2008) Autoantibodies against modified apolipoprotein B-100 in relation to low-density lipoprotein size and the metabolic syndrome in otherwise healthy men. Metabolism 57:362–366. doi:10.1016/j.metabol.2007.10.011 CrossRefPubMed

43.

Sjogren P, Fredrikson GN, Samnegard A, Ericsson CG, Ohrvik J, Fisher RM, Nilsson J, Hamsten A (2008) High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 29:2218–2226. doi:10.1093/eurheartj/ehn336 CrossRefPubMed

44.

Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, Nilsson J (2003) Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 23:879–884. doi:10.1161/01.ATV.0000067937.93716.DB CrossRefPubMed

45.

Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK (1998) Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 102:910–918. doi:10.1172/JCI119892 CrossRefPubMed

46.

Caligiuri G, Nicoletti A, Poirier B, Hansson GK (2002) Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109:745–753PubMed

47.

Schiopu A, Bengtsson J, Soderberg I, Janciauskiene S, Lindgren S, Ares MP, Shah PK, Carlsson R, Nilsson J, Fredrikson GN (2004) Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 110:2047–2052. doi:10.1161/01.CIR.0000143162.56057.B5 CrossRefPubMed

48.

Fredrikson GN, Bjorkbacka H, Soderberg I, Ljungcrantz I, Nilsson J (2008) Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J Intern Med 264:563–570. doi:10.1111/j.1365-2796.2008.01995.x CrossRefPubMed

49.

van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, van der Zee R, van Eden W, van Berkel TJ, Kuiper J (2006) Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114:1968–1976. doi:10.1161/circulationaha.106.615609 CrossRefPubMed

50.

Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, Libby P, Weiner HL (2002) Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106:1708–1715. doi:10.1161/01.CIR.0000029750.99462.30 CrossRefPubMed

51.

George J, Yacov N, Breitbart E, Bangio L, Shaish A, Gilburd B, Shoenfeld Y, Harats D (2004) Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta2-glycoprotein I. Cardiovasc Res 62:603–609. doi:10.1016/j.cardiores.2004.01.028 CrossRefPubMed

52.

Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760. doi:10.1146/annurev.immunol.20.100301.064842 CrossRefPubMed

53.

Hansson GK, Holm J, Jonasson L (1989) Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135:169–175PubMed

54.

Zhou X, Paulsson G, Stemme S, Hansson GK (1998) Hypercholesterolemia is associated with a Th1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 101:1717–1725. doi:10.1172/JCI1216 CrossRefPubMed

55.

Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH (2005) T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 102:1596–1601. doi:10.1073/pnas.0409015102 CrossRefPubMed

Title: Vaccination against atherosclerosis? Induction of atheroprotective immunity
Authors: Göran K. Hansson
Jan Nilsson
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 1/2009
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-009-0151-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

The emerging role of the endocannabinoid system in cardiovascular disease

Innate and adaptive immunity in atherosclerosis

Myeloid cells in atherosclerosis: initiators and decision shapers

Update on statin-mediated anti-inflammatory activities in atherosclerosis

Cytokine network and T cell immunity in atherosclerosis

Connexins participate in the initiation and progression of atherosclerosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials